Hepatocellular (liver) cancer
Post period end, we announced the commencement of NBTXR3 development in a third
indication, liver cancer. Liver cancer is a major global health problem with an
estimated 695,000 deaths per annum worldwide.
To help accelerate this programme, we have been awarded a €2.8 million grant
from Bpifrance through its Strategic Industrial Innovation (ISI) program.
Bpifrance (formerly OSEO) allocated c.€9 million in funding to the NICE (Nano
Innovation for CancEr) consortium, consisting of Nanobiotix and four other
public and private partners. Through ETPN (European Technology Platform of
Nanomedicine), Nanobiotix is driving nanomedicine in Europe and is now involved
in this first nanomedicine consortium in France with the launch of the NICE
Since August 2012, Nanobiotix has a strategic partnership in place with
PharmaEngine for the development of NBTXR3 in the Asia region. PharmaEngine is a
specialty pharma company focused on the development of in-licensed oncology
drugs and has exclusive rights to develop and commercialize NBTXR3 in the Asian-
Pacific region. Nanobiotix received an upfront payment of US$1 million (€811k)
and is eligible to further payments upon agreed milestones.
The partnership is progressing with the preparation of clinical studies in
potential key indications such as head and neck, oesophageal, liver and rectal
Lead candidate selection - NBTX-IV
NBTX-IV is the second product generated from Nanobiotix's proprietary NanoXray
platform. In June, Nanobiotix selected the lead candidate (see NCI-NCL section
below). The product is designed to be administered intravenously to target deep-
seated tumors and lymph nodes which may have been invaded locally by cancer
cells. The aim is to enhance radiotherapy energy to destroy cancer cells and to
reduce the subsequent escape of malignant cells in neighbouring tissue cells or
lymph nodes. Target indications include lung carcinoma, pancreatic cancer or
Collaboration with the National Cancer Institute (NCI) with NBTX-IV
The NCI-NCL has selected NBTX-IV for preclinical characterization to support
Nanobiotix's filing of an Investigational New Drug (IND) with the FDA. In
parallel, Nanobiotix will conduct additional pre-clinical testing to provide a
complete dossier for submission.
This collaboration with the NCL, planned to commence in H2 2013, will accelerate
the preclinical development of NBTX-IV. The results of the characterization are
not only important for the future IND submission, but also to raise Nanobiotix's
profile in the US market.
Product development - NBTX-TOPO
The third product from the NanoXray platform is in the form of a topical
application, developed to be used to fill tumor cavities during surgery. The
product is intended for different types of breast cancer, brain tumors and
retroperitoneal soft tissue sarcomas. It could also be used to delineate the
tumor in CT scans and to prepare the tumor bed for postoperative radiotherapy.
NBTX-TOPO is still at an early stage of development.